Profusa (NASDAQ:PFSA) Major Shareholder Financial Lp Hrt Buys 14,556 Shares of Stock

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt purchased 14,556 shares of Profusa stock in a transaction on Monday, August 3rd. The stock was bought at an average cost of $0.96 per share, with a total value of $13,973.76. Following the transaction, the insider directly owned 108,301 shares of the company’s stock, valued at approximately $103,968.96. The trade was a 15.53% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, August 4th, Financial Lp Hrt purchased 1,368 shares of Profusa stock. The shares were bought at an average price of $0.95 per share, with a total value of $1,299.60.
• On Wednesday, July 29th, Financial Lp Hrt acquired 1,310 shares of Profusa stock. The shares were bought at an average cost of $1.01 per share, for a total transaction of $1,323.10.

Profusa Stock Performance

Shares of NASDAQ PFSA opened at $0.94 on Thursday. The business’s 50-day simple moving average is $3.73 and its 200-day simple moving average is $33.53. Profusa, Inc. has a 52 week low of $0.86 and a 52 week high of $1,297.50. The firm has a market cap of $178,771.00, a price-to-earnings ratio of -0.00 and a beta of 0.52.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.